Split Fed. Circ. Upholds Mylan's Win In Axing Tecfidera Patent

By Dani Kass (November 30, 2021, 8:19 PM EST) -- A West Virginia federal judge rightfully invalidated a patent covering Biogen's blockbuster multiple sclerosis drug Tecfidera, negating the need to see whether the Patent Trial and Appeal Board should have done so as well, the Federal Circuit said Tuesday.

Nearly a year after oral arguments, the appeals court issued a 2-1 precedential opinion upholding U.S. District Judge Irene M. Keeley's patent invalidation based on written description concerns — its second major written description opinion in a week. The panel on Tuesday also released a unanimous nonprecedential decision saying it's now unnecessary to determine whether the PTAB should have found the same patent invalid...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!